NANOBIOTIX Appoints Arnd Christ as CFO

NANOBIOTIX, a clinical-stage biotechnology company, announced the appointment of Arnd Christ as Chief Financial Officer, effective October 1, 2026. With over 25 years of experience in financial leadership roles at publicly listed biotech firms across Europe and the U.S., Christ is set to join the company's executive board. He replaces Bart Van Rhijn, who served the company for five years.

Christ's previous roles include CFO at Immatics N.V., InflaRx N.V., MediGene AG, and others. He has considerable expertise in IPOs, licensing deals, and fundraising activities. Laurent Levy, co-founder and chairman, emphasizes Christ's experience as crucial for Nanobiotix's growth phase.